Copyright 2016 Biomedical Microdevices Laboratory
 Y Zhang, CB Ballas, and MP Rao. IEEE EMBC 2012.
 Y Zhang, D Nampe, HG Dixit, CB Ballas, H Tsutsui, and MP Rao. MMB 2013.
Top: Scanning electron micrograph of a
single capture site within a UHT
mechanoporation device with 10k
capture sites. Bottom: Flow cytometry
results showing poration efficiency for
K562 human leukemia cells .
Research in this thrust focuses on developing
novel MEMS-based microinjection instrumentation
that may eventually serve as a fundamental
enabler for cell-based therapies.
Microinjection represents the "gold standard" for
cellular manipulation, due to its precision, safety,
and applicability to a wide variety of cell types and
molecules. However, the reliance of conventional
microinjection instrumentation upon manual
operation and serialized injection limits throughput
(~3 cells/min). This therefore precludes its use for
ex vivo cell therapies, where microinjection could
address safety concerns associated with prevailing
bulk manipulation techniques (e.g. viral vectors,
electroporation, & lipofection).
The Si-based ultrahigh throughput (UHT)
mechanoporation device shown here represents
the first step towards addressing this limitation.
The key novelty of this device lies in its monolithic
integration of cell capture and poration functions,
as well as its massive-parallelization, which
provides opportunity for UHT operation with
minimal human or robotic involvement. Thus far,
we have demonstrated devices capable of
throughputs > 1k cells/min, which exceeds the
state-of-the-art by 2 - 3 orders of magnitude and
begins to approach the throughputs required for
clinical relevance [1,2].
CB Ballas, Indiana Univ SoM, Hematology/Oncology
H Tsutsui, ME, UCR